1,736 results on '"Lund, Lars H."'
Search Results
2. Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure
3. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
4. Epigenetic modulators link mitochondrial redox homeostasis to cardiac function in a sex-dependent manner
5. The Longest Living Patient Supported With Left Ventricular Assist Device (14 Years)
6. Novel Trial Designs in Heart Failure: Using Digital Health Tools to Increase Pragmatism
7. Inflammation and myeloperoxidase – The next treatment targets in heart failure?
8. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry
9. Insights into RC time Curve fit analysis of pulmonary artery pressure decay
10. Acyl ghrelin increases cardiac output while preserving right ventricular‐pulmonary arterial coupling in heart failure
11. External validation of a deep learning algorithm for automated echocardiographic strain measurements
12. Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
13. Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
14. Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: Insights from the Swedish Heart Failure Registry
15. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic
16. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry
17. Reply by Shahim et al. to Letter “Aortic regurgitation for adverse cardiovascular events: really harmless or just hidden?” Regarding Article “Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and Reduced, Mildly Reduced, and Preserved Ejection Fraction: An Analysis of the ESC Heart Failure Long‐Term Registry”
18. Clinical Features of Heart Failure With Normal Ejection Fraction
19. Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization
20. Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease – no heterogeneity
21. Acyl ghrelin infusion increases circulating growth hormone in patients with heart failure and reduced ejection fraction
22. Identifying distinct clinical clusters in heart failure with mildly reduced ejection fraction
23. Generalizable Approach to Quantifying Guideline-Directed Medical Therapy
24. Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction
25. Does Heterogeneity Exist in Treatment Associations With Renin–Angiotensin–System Inhibitors or Beta-blockers According to Phenotype Clusters in Heart Failure with Preserved Ejection Fraction?
26. Global Public Health Burden of Heart Failure: An Updated Review
27. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
28. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline‐recommended treatments: An analysis from the Swedish Heart Failure Registry
29. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology
30. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long‐Term Registry
31. Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study
32. Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real‐world heart failure population
33. Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
34. Comprehensive Characterization of Non-Cardiac Comorbidities in Acute Heart Failure- an analysis of ESC-HFA EORP Heart Failure Long-Term Registry
35. Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF
36. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
37. Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction
38. Iron deficiency in heart failure: screening, prevalence, incidence and outcome Data from the Swedish Heart Failure registry and the Stockholm CREAtinine Measurements collaborative project
39. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association ( HFA ) of the ESC
40. Sex Differences in the Generalizability of Randomized Clinical Trials in Heart Failure with Reduced Ejection Fraction
41. What determines who gets Cardiac Resynchronization Therapy in Europe? A comparison between ESC-HF-LT registry, SwedeHF registry and ESC-CRT Survey II
42. Optimizing outcomes in heart failure: 2022 and beyond
43. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results
44. Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure
45. Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization
46. Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
47. Use of and association between heart failure pharmacological treatments and outcomes in obese versus non‐obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
48. Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
49. A machine learning model for prediction of 30-day primary graft failure after heart transplantation
50. Personalized care of patients with heart failure: are we ready for a REWOLUTION ? Insights from two international surveys on healthcare professionals' needs and patients' perceptions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.